Loading...
Market
What will be the next major corporate action by Cybin by end of 2025?
2
Resolution / Starting Odds
Merger or acquisition • 25%
New major partnership • 25%
Launch of another Phase 3 trial • 25%
Other • 25%
Cybin's official announcements and financial news outlets
Story
Cybin Reports 100% Response Rate, 71% Remission in Phase 2 Trial for CYB003; Stock Up 20.7%
Nov 18, 2024, 12:08 PM
Cybin Inc. has announced positive results from its Phase 2 clinical trial for CYB003, a treatment for Major Depressive Disorder (MDD). The trial revealed that 100% of participants responded to the treatment, with 71% achieving remission after just two doses of 16 mg each over a 12-month period. Following these promising results, Cybin has initiated the Phase 3 PARADIGM TM multinational pivotal program to further evaluate the efficacy and safety of CYB003. The stock price of Cybin has seen a pre-market increase of 20.7% as a result of this announcement.
View original story
Similar markets
Launch a new drug • 25%
Enter a new partnership • 25%
Expand into new markets • 25%
No major changes • 25%
Pfizer • 25%
Johnson & Johnson • 25%
Novartis • 25%
Roche • 25%
Merger • 25%
Acquisition • 25%
Partnership • 25%
No significant action • 25%
Pfizer • 25%
Johnson & Johnson • 25%
Merck • 25%
Other • 25%
New Alzheimer's drug candidate announced • 25%
Focus shifts to different therapeutic area • 25%
Company gets acquired • 25%
Continues current operations without major changes • 25%
Johnson & Johnson • 25%
Pfizer • 25%
Novartis • 25%
Other • 25%
Yes • 50%
No • 50%
Increase Bitcoin holdings • 25%
Invest in another cryptocurrency • 25%
Invest in traditional assets • 25%
No major investment move • 25%
Pharmaceutical company • 25%
Government agency • 25%
Research institution • 25%
Other • 25%